New and emerging treatments for ulcerative colitis: a focus on vedolizumab
Tamsin Gledhill,1 Keith Bodger21Digestive Diseases Centre, Aintree University Hospital Trust, 2Gastroenterology Department, Institute of Translational Medicine, University of Liverpool, Liverpool, UKAbstract: Ulcerative colitis (UC) is the most common form of chronic inflammatory bowel disease and l...
Guardado en:
Autores principales: | Gledhill T, Bodger K |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/df0a4f9f36d540c88a56d09b35666d56 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Selective biologics for ulcerative colitis and Crohn's disease – clinical utility of vedolizumab
por: Petkau JM, et al.
Publicado: (2016) -
Infliximab in ulcerative colitis
por: Avi Levin, et al.
Publicado: (2008) -
Machine learning using clinical data at baseline predicts the efficacy of vedolizumab at week 22 in patients with ulcerative colitis
por: Jun Miyoshi, et al.
Publicado: (2021) -
Golimumab in unresponsive ulcerative colitis
por: Lippert E, et al.
Publicado: (2014) -
Pediatric ulcerative colitis: current treatment approaches including role of infliximab
por: Bradley GM, et al.
Publicado: (2012)